SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

dc.contributor.authorLi, Dandan
dc.contributor.authorShi, Weilong
dc.contributor.authorWang, Tiansheng
dc.contributor.authorTang, Huilin
dc.contributor.departmentEpidemiology, School of Public Healthen_US
dc.date.accessioned2018-04-27T17:02:14Z
dc.date.available2018-04-27T17:02:14Z
dc.date.issued2018
dc.description.abstractTo assess the efficacy and safety of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase‐4 (DPP‐4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta‐analysis of 14 randomized controlled trials (RCTs) involving 4828 patients. Compared with a DPP‐4 inhibitor, SGLT2 inhibitor/DPP‐4 inhibitor combination therapy was significantly associated with a decrease in glycaemic control (HbA1c, −0.71%; fasting plasma glucose [FPG], −25.62 mg/dL; postprandial plasma glucose, −44.00 mg/dL), body weight (−2.05 kg) and systolic blood pressure (−5.90 mm Hg), but an increase in total cholesterol (TC) of 3.24%, high‐density lipoprotein of 6.15% and low‐density lipoprotein of 2.55%. Adding a DPP‐4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by −0.31%, FPG by −8.94 mg/dL, TC by −1.48% and triglycerides by −3.25%. Interestingly, low doses of an SGLT2 inhibitor in the combination has similar or even better efficacy in some aspects than high doses. Similar adverse events were observed for the combination therapy, with the exception of genital infection vs DPP‐4 inhibitor (risk ratio [RR], 5.31) and consistent genital infection vs an SGLT2 inhibitor (RR, 0.61). Further studies are warranted to confirm these results.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationLi D., Shi W., Wang T., & Tang H. (2018). SGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 0(0). https://doi.org/10.1111/dom.13294en_US
dc.identifier.urihttps://hdl.handle.net/1805/15943
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1111/dom.13294en_US
dc.relation.journalDiabetes, Obesity and Metabolismen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectSGLT2 inhibitorsen_US
dc.subjectDPP-4 inhibitoren_US
dc.subjecttype 2 diabetesen_US
dc.titleSGLT2 inhibitor plus DPP‐4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta‐analysisen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Li_2018_SGLT2.pdf
Size:
305.4 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: